COMP <GO>
LFVN vs JNJ // FORWARD P/E MULTIPLE
Lifevantage Corporation (Delaware) (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: LFVN 7
— JNJ 5
▲ FORWARD P/E MULTIPLE LEADER: LFVN
LAST: $5.88 (+0.17%) • MKT CAP: $73.9M
forward-pe
6.3x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LFVN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LFVN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.40% | 67.90% | +12.50 | LFVN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.20% | 25.50% | +3.70 | LFVN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.5x | 18.5x | -13.00 | LFVN | /valuation <GO> |
| Free Cash Flow Yield | 14.22% | 2.97% | +11.25 | LFVN | /fcf-yield <GO> |
| Operating Margin | 5.30% | 34.70% | -29.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 4.30% | 28.50% | -24.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 14.20% | 6.00% | +8.20 | LFVN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.80% | 0.00% | +2.80 | LFVN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.98 | 5.59 | -1.61 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.6 | 62.1 | -12.48 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 6.3x | 23.0x | -16.70 | LFVN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $73.9M | $662.49B | -$662.42B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LFVN REV | JNJ REV | LFVN GROSS % | JNJ GROSS % | LFVN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $228.5M | $94.19B | 80.4% | 67.9% | $10.5M | $19.70B |
| FY 2024 | $200.2M | $88.82B | 79.3% | 69.1% | $10.0M | $19.84B |
| FY 2023 | $213.4M | $85.16B | — | — | $6.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LFVN // BETA —
JNJ // BETA 1.08